Condition: Rhegmatogenous Retinal Detachment · Proliferative Vitreoretinopathy · Sponsor: Massachusetts Eye and Ear Infirmary
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
This description comes directly from the study's public registry record.
Leo Kim, MD, PhD · 6175237900 · Leo_Kim@meei.harvard.edu
Center for Clinical Research Operations (CCRO) · 6175736060
Always discuss trial participation with your own doctor first.
| Mass Eye and Ear | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06033703